Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

EBS - Emergent BioSolutions Inc. Последние... | Finranks

Home

EBS

E

Emergent BioSolutions Inc. (EBS)

NYQ – Цена в реальном времени. Валюта: USD

7.93

-0.15 (-1.86%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

8.00

+0.07 (0.88%)

После закрытия: Mar 27, 2026, 7:45 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D.

Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture

Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture

Emergent BioSolutions faces a sharp reset in 2026 guidance, with revenue projected at $720–$760 million, well below prior expectations. 2025 profitability was buoyed by favorable mix, cost controls, and a one-time $60 million order, but these drivers are not expected to recur. Competitive pressure on naloxone and uneven government procurement drive margin compression and revenue unpredictability, with adjusted EBITDA guided down to $135-$155 million in 2026.

Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript

Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript

Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025.

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company's common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company's common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares.

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada's biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and Canada and reinforce Canada's commitment to long-term readiness and advanced strategic stockpiling. Emergent will receive more than $35M million CAD in orders in 2026.

Видео

No Data

There is no data to display

Пресс-релизы

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for additional doses of VIGIV, a treatment for complications due to smallpox vaccination.

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D.

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025.

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company's common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company's common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares.